The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

Core Viewpoint - MoonLake Immunotherapeutics' stock price plummeted over 90% following the release of disappointing week-16 results from its Phase 3 VELA-1 and VELA-2 trials for sonelokimab, despite achieving statistical significance in primary and secondary endpoints [1][8]. Group 1: Trial Design and Results - A total of 838 patients were enrolled in the VELA trials, which compared a single 120mg dose of sonelokimab to placebo, with primary endpoint HiSCR75 assessed at week 16 [2]. - Both VELA-1 and VELA-2 trials achieved statistical significance for all key endpoints, including lesion counts and patient-reported outcomes, with p-values below 0.001 [3]. - Sonelokimab showed a statistically significant HiSCR75 response as early as week 4 in both studies [3]. Group 2: Efficacy and Patient Outcomes - At week 16, 34.8% of patients in VELA-1 and 35.9% in VELA-2 achieved HiSCR75, while placebo response rates were 17.5% and 25.6%, respectively [5]. - Approximately 30% of patients reported a significant reduction in pain, with at least a 3-point improvement in the worst pain NRS in both trials [6]. - Nearly 60% of patients experienced a meaningful improvement of 4 points or more in the Dermatology Quality of Life Index (DLQI), representing a 20 percentage-point benefit over baseline [7]. Group 3: Safety and Future Outlook - The safety profile of sonelokimab remained favorable, consistent with previous studies, and no new safety signals were reported [7]. - Preliminary analyses indicate that responses may continue to improve beyond week 16, with placebo patients achieving similar responses to those initially randomized to sonelokimab by week 20 [4].